前列腺癌根治术后生化复发对总死亡的影响:基于SEARCH数据库的寿命损失年分析
该研究基于SEARCH数据库7820例根治性前列腺切除术患者,其中2846例(36%)出现生化复发。生化复发与总死亡风险轻度升高相关(HR 1.29,p<0.001),中位复发时剩余寿命为无复发组16.7年、复发组15.3年,损失1.4年。PSADT<3个月者损失6.8年,3-8.9个月者损失2.8年。
要点
- 生化复发与总死亡风险轻度升高相关,HR 1.29。
- 中位复发时生化复发组损失1.4年寿命。
- PSADT<3个月者寿命损失达6.8年,需强化挽救治疗。
核心结论
- 根治性前列腺切除术后生化复发与总死亡风险轻度升高(HR 1.29)及1.4年寿命损失相关。
- PSADT<9个月的生化复发亚组总死亡风险显著更高,寿命损失达3-7年。
研究设计与样本
- SEARCH数据库回顾性队列研究,纳入7820例根治性前列腺切除术患者,其中2846例(36%)出现生化复发。
- 采用Cox模型(生化复发为时间依赖协变量)评估总死亡关联,采用Poisson回归估计寿命损失年。
主要发现
- 多因素分析显示生化复发与总死亡风险升高相关(HR 1.29;p<0.001)。
- 按PSADT分层,仅PSADT<3个月或3-8.9个月亚组的总死亡风险显著高于无复发组(均p<0.001)。
- 中位复发时,无复发组剩余寿命16.7年,生化复发组15.3年,损失1.4年。
- PSADT<3个月者寿命损失6.8年,PSADT 3-8.9个月者损失2.8年,PSADT>9个月者损失<1年。
关键数值与推荐
- 多因素分析总死亡风险HR 1.29(p<0.001)。
- 中位复发时剩余寿命:无复发组16.7年 vs 生化复发组15.3年,寿命损失1.4年。
- PSADT<3个月者寿命损失6.8年,PSADT 3-8.9个月者2.8年,PSADT>9个月者<1年。
临床怎么用
- 可利用寿命损失年数据为生化复发患者提供以患者为中心的预后咨询。
- 对PSADT<9个月的高危生化复发患者,应考虑强化挽救治疗。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The impact of biochemical recurrence (BCR) of prostate cancer after radical prostatectomy (RP) on overall mortality (OM) remains uncertain. Specifically, there are no patient-centered quantitative data on the impact of BCR on life expectancy. We compared OM and remaining lifetime between groups of patients with and without BCR after RP. METHODS: We identified 7820 participants who underwent RP, of whom 2846 (36%) had BCR. Associations between BCR and OM were assessed via Cox models with BCR as a time-dependent covariate. Years of life lost (YLL) associated with BCR (difference in remaining lifetime between the BCR and no-BCR groups) was estimated via Poisson regression. In secondary analyses the BCR group was stratified by prostate-specific antigen doubling time (PSADT). KEY FINDINGS AND LIMITATIONS: BCR was associated with modestly higher risk of OM on multivariable analysis (hazard ratio 1.29; p < 0.001). On PSADT stratification, only the BCR subgroups with PSADT of <3 mo or 3-8.9 mo had significantly higher OM risk in comparison to the group without BCR on multivariable analysis (both p < 0.001). At the median time to recurrence, remaining lifetime was 16.7 yr for the group without BCR and 15.3 yr for the BCR group (1.4 YLL). YLL stratified by PSADT subgroup was 6.8 yr for PSADT <3 mo, 2.8 yr for PSADT 3-8.9 mo, and <1 yr for PSADT >9 mo. Early salvage radiation and/or hormonal therapy was more common in the BCR subgroup with PSADT <9 mo (p < 0.001). CONCLUSIONS AND CLINICAL IMPLICATIONS: BCR after RP was significantly associated with a modest increased in the risk of OM and 1.4 YLL. In the BCR subgroup with PSADT <9 mo, the OM risk was dramatically higher, with 3-7 YLL, despite more frequent and earlier secondary treatment. These results quantify YLL associated with high-risk BCR for the first time, and can support patient-centered discussion and consideration of intensified salvage treatment validated in recent clinical trials and regimens recommended in clinical practice guidelines.
引用
- Zheng R, Tang Y, Daskivich TJ, et al. Quantifying the Impact of Biochemical Recurrence After Radical Prostatectomy on Overall Mortality by Years of Life Lost: Results from the SEARCH Database. Eur Urol Oncol. 2025. PMID: 41478783. doi:10.1016/j.euo.2025.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。